Medication info
Lowtec Plus Tablet 20/12.5 mg

Lowtec Plus Tablet 20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
SS Pharm Co., Ltd.
Appearance
Round film-coated tablets with a reddish-yellow color
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201308504 · Approved 2013.07.30 · Insurance code 652604820

Summary

Main use
Treatment of essential hypertension not adequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before starting this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. In patients taking a high-dose hydrochlorothiazide single-ingredient product and in patients with volume depletion or hyponatremia, concomitant administration of olmesartan medoxomil or switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) may result in a marked reduction in blood pressure. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before starting concomitant olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbidities, and other concomitant medicines. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild or moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic impairment.
Child dose
<Pediatrics> The safety and efficacy in children have not been established.

Ingredients

Manufacturer
SS Pharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not adequately controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan Medoxomil and Hydrochlorothiazide are medications used in the treatment of essential hypertension. When blood pressure control is difficult with monotherapy, this combination effectively helps lower blood pressure. Olmesartan Medoxomil works by relaxing blood vessels to reduce blood pressure, while Hydrochlorothiazide aids in controlling blood pressure by promoting the excretion of salt and water through diuresis. This combination improves blood pressure management and helps reduce the risk of cardiovascular complications. Therefore, the combination therapy of Olmesartan Medoxomil and Hydrochlorothiazide is an effective choice for treating essential hypertension.

How to take

Adult dose

Before starting this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. In patients taking a high-dose hydrochlorothiazide single-ingredient product and in patients with volume depletion or hyponatremia, concomitant administration of olmesartan medoxomil or switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) may result in a marked reduction in blood pressure. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before starting concomitant olmesartan medoxomil. <Elderly patients> In elderly patients, start at the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbidities, and other concomitant medicines. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild or moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic impairment.

Child dose

<Pediatrics> The safety and efficacy in children have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to ingredients in this medication or patients with severely impaired kidney or liver function, specific electrolyte imbalances, or certain diseases should avoid using this medication. In patients with diminished blood volume, renal impairment, or heart or liver problems, this medication should be used cautiously, with careful observation for symptoms such as hypotension or changes in kidney function. This medication can affect electrolyte balance, particularly levels of potassium, sodium, calcium, and magnesium, making regular blood tests necessary. Dizziness may occur during treatment, so it’s advisable to avoid driving or operating dangerous machinery. This medication can trigger photosensitivity reactions, increasing the risk of skin cancer, so sun exposure should be limited and protective measures taken. During treatment, attention should be paid to drug interactions, especially when taken with potassium supplements, diuretics, lithium, or non-steroidal anti-inflammatory drugs; a doctor should be consulted in such cases. Nursing women should consult a doctor before use, as this drug can pass into breast milk and affect the baby. Safety and efficacy in children and older adults have not been sufficiently established, so caution is advised. Overdose can lead to symptoms such as hypotension, electrolyte imbalance, and dehydration, necessitating immediate medical attention.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, increased creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, hair loss, pruritus, urticaria, rhabdomyolysis, acute renal failure, increased serum creatinine, palpitations, elevated blood pressure, epistaxis, asthma, loss of appetite, dry mouth, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, temporary blurred vision, yellowing, choroidal exudate, hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, facial flushing, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, chronic malabsorption syndrome, intestinal vascular edema, chronic diarrhea, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus, parathyroid disorder, muscle cramps, sensory disturbances

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. A cool place with temperatures between 1 and 25 degrees Celsius is suitable for storage.

Appearance and packaging

Appearance

Round film-coated tablets with a reddish-yellow color

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.